Polyrizon (PLRZ) said Friday that it has signed a non-binding letter of intent with an unidentified company specializing in psychedelic-based therapies to develop a novel intranasal formulation using Polyrizon's proprietary platform to improve the delivery of psychedelic treatments.
Polyrizon said it will develop the formulation using its mucoadhesive technology, while the psychedelic-focused company will fund the research and development, including feasibility studies.
After establishing proof of concept, both parties intend to finalize a definitive agreement on intellectual property, royalties, commercialization rights, and financial terms, Polyrizon said.
Shares of the company were down nearly 20% in recent premarket activity on Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.